SPOPL

Across TCGA pan-cancer cohorts, SPOPL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPOPL data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SPOPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPOPL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and BRCA are the cancer types where SPOPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.158	0.720	<.001	33	view →
COAD	OS	Median	III,IV	0.082	0.792	<.001	24	view →
BRCA	DFS	Median	All	0.433	0.903	.001	22	view →
UCEC	DFS	Median	All	0.927	0.595	.005	16	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPOPL–BLCA (OS)

Open the BLCA breakdown →